| Date | Title | Description |
| 22.09.2022 | Embattled CEO Werner Baumann enters his final chapter at Bayer, aiming to turn the German pharma giant into a cancer powerhouse | Werner Baumann, the CEO of Bayer AG. Wolfgang Rattay/Reuters This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
With a search for a successor underway, Werner Baumann is entering ... |
| 29.12.2021 | Meet the 28 startups the biggest investor in biotech is betting on this year | Robert Nelsen, Arch Venture Partners' cofounder and managing partner. ARCH This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider analyzed more than 90 IPOs to find the top venture-capit... |
| 06.08.2021 | Bitcoin mining is having a moment right now, but will it last? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Hurl whatever skepticism you want at Bitcoin, but the process of mining the cryptocurrency is, we... |
| 05.08.2021 | Bayer : strengthens drug discovery platform through acquisition of Vividion Therapeutics | Thursday - August 5, 2021 Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
Acquisition strengthens Bayer's drug discovery capabilities with cutting-edge chemoproteomics platform / Vividion's unique appr... |
| 24.02.2021 | Vividion Announces $135M Series C Financing |
SAN DIEGO, CA, Vividion Therapeutics, a biotechnology company, announced the completion of a $135M Series C financing, co-led by Logos Capital and Boxer Capital.
>> Click here for more funding data on Vividion Therapeutics
>>... |
| 24.02.2021 | Vividion Therapeutics has raised a $135M Series C, which may enable the company to conduct an IPO | - |
| 24.02.2021 | Biotech Vividion lands $135M in crossover cash, paving a path to the public markets | The Series C round of financing announced Wednesday included so-called crossover investors, firms that invest in both public and private companies. Securing crossover investment is one of the steps companies take as they prepare for an IPO.... |
| 05.05.2019 | Vividion’s ‘Unique’ Platform Draws $82M Series B Round | Vividion’s Paige Schaffer works in the company’s lab at its prior location. The company’s drug-discovery platform targets “undruggable” proteins. Photo by Jamie Scott Lytle.
Vividion Therapeutics — which formed to transform drug development... |
| 01.05.2019 | Term Sheet — Wednesday, May 1 | WHO KNOWS?
What’s SoftBank up to now?
Paid Content You can't secure what you can't see From ExtraHop
He also dropped more news around its plans to start fundraising for a second investment vehicle that will be “the same size” as its $100 bi... |
| 30.04.2019 | Vividion Therapeutics Secures $82M Series B Round |
SAN DIEGO, CA, Vividion Therapeutics today announced the completion of an oversubscribed $82 Million Series B financing.
>> Click here for more funding data on Vividion Therapeutics
>> To export Vividion Therapeutics funding... |
| 30.04.2019 |
Vividion Therapeutics Raises $82M More
| San Diego-based Vividion Therapeutics, a biopharmaceuticals startup working on small molecule drugs, hsa raised $82M in a Series B funding round, the company said this morning. The funding--which the company said was oversubscribed--was led... |
| 30.04.2019 | Vividion Therapeutics Raises $82M | Vividion Therapeutics, a biotechnology company with a revolutionary platform to discover small molecule therapeutics against biologically compelling but previously intractable targets, today announced the completion of an oversubscribed $82... |
| 30.04.2019 | Vividion Therapeutics Raises $82M in Series B Financing | Vividion Therapeutics, a San Diego, CA-based biotechnology company with a platform to discover small molecule therapeutics against biologically compelling but previously intractable targets, closed an $82M Series B financing.
The round was ... |
| 23.03.2019 | Corporate biotech venture funding rises again | Joanna Glasner Contributor
More posts by this contributor
Everyone loves pizza, including VCs
Which public US universities graduate the most funded founders?
Biotech venture funding has been on a tear for the past couple of years, and corpo... |
| 19.03.2019 | Corporate Biotech Venture Funding Rises Again | 51 Shares Email Facebook Twitter LinkedIn
Biotech venture funding has been on a tear for the past couple years, and corporate investors in the space are doing their part to boost the totals.
Here at Crunchbase, we’ve put together an index o... |
| 02.02.2018 | Vividion Therapeutics launches with $50M pledged from Arch Venture Partners and Versant Ventures | - |
| 02.02.2017 | ARCH Venture Partners Leads $50M Series A for Vividion Therapeutics | SAN DIEGO--(BUSINESS WIRE)--ARCH Venture Partners and Versant Ventures today announced the launch of Vividion Therapeutics, Inc., a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs us... |
| 02.02.2017 | Scripps spin-out Vividion launches with $50M | The startup incorporated in 2013. Since then, it has been operating in stealth mode, a status that was given away earlier this month when it filed a Form D with the SEC as part of its bid to raise just over $50 million.
Vividion’s technolog... |
| 02.02.2017 | Term Sheet — Thursday, February 2 | ET CETERA
Hello from the Upfront Ventures conference in Los Angeles, where, aside from sushi, all anyone can talk about is politics. A few notes on that:
Paid Content What you need to know about growing cyberattacks From ExtraHop
Just look ... |
| 02.02.2017 | Vividion Therapeutics Raises $50M in Series A Financing | Vividion Therapeutics, a San Diego, CA-based biotechnology company, raised $50M in Series A financing.
Founding investors are ARCH Venture Partners and Versant Ventures. In conjunction with the financing, Tom Daniel, M.D., Executive Chairma... |
| 02.02.2017 |
Vividion Therapeutics Raises $50M
| San Diego-based Vividion Therapeutics, a biopharmaceuticals firm tapping into technology developed at The Scripps Research Insitute, has raised $50M in a Series A funding round. The funding was led by ARCH Venture Partners and Versant Ventu... |
| 02.02.2017 | Cardinal Partners Joins $50M Series A for Vividion Therapeutics | SAN DIEGO--(BUSINESS WIRE)--ARCH Venture Partners and Versant Ventures today announced the launch of Vividion Therapeutics, Inc., a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs us... |
| 02.02.2017 | Vividion Therapeutics Raises $50 Million | Local biopharmaceutical company Vividion Therapeutics has raised $50 million in a Series A funding round.
The funding was led by two top-tier venture capital firms, ARCH Venture Partners and Versant Ventures, and also included Cardinal Part... |
| - | The German giant Bayer is remaking its pharma business, betting billions on a flurry of new deals for cutting-edge science. Wall Street is still forecasting a sales dip. | Marianne De Backer, Bayer's chief business officer. Bayer This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Bayer is spending billions on cell and gene therapies to drive its pha... |
| - | Scripps spin-out Vividion launches with $50M | There’s a new proteomics platform in town and it has rallied some serious coin.
Vividion Therapeutics launched on Thursday with $50 million in Series A financing led by ARCH Venture Partners and Versant Ventures, with support from founding ... |
| - | Biotech Vividion lands $135M in crossover cash, paving a path to the public markets | Vividion Therapeutics has technology that finds ways to hit promising disease targets that were previously deemed “undruggable.” Now it has $135 million that might allow it to find something else: a public stock listing.
The Series C round ... |
| - | Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs | SAN DIEGO--(BUSINESS WIRE)--Feb 24, 2021--
Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cance... |
